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The increased availability of high-throughput molecular testing since the turn of the century
has revealed a more detailed picture of organisms that may be present in the vagina than was
possible when diagnosis depended on microscopy, culture, and—in the case of sexually trans-
mitted infection (STI) pathogens—polymerase chain reaction (PCR). While past research
focused individually on STIs, bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and
vaginal carriage of Streptococcus agalactiae as a cause of neonatal disease, new understandings
of the interrelationships among vaginal organisms, and their effects on the cervicovaginal
mucosal barrier and immune system, have advanced understanding of relationships between
the vaginal microbiome and a variety of adverse outcomes, including HIV acquisition, pelvic
inflammatory disease, miscarriage, preterm birth, and invasive maternal and neonatal infec-
tions [1–4].
Healthy and dysbiotic vaginal environments
While a cervicovaginal mucosa covered with lactobacilli is still considered the optimal envi-
ronment, molecular studies have shown that not all lactobacilli are equal [1]. Lactobacillus cris-
patus only occasionally co-occurs with organisms other than lactobacilli, has been associated
with an anti-inflammatory cervicovaginal immune profile, and seems to protect women from
developing anaerobic dysbiosis and from the above-mentioned adverse outcomes [1–5]. In
contrast, L. iners does not seem to protect women from developing anaerobic dysbiosis and
often co-occurs with BV-associated anaerobes, pathobionts (streptococci, staphylococci, or
Enterobacteriaceae), or pathogens [1–6]. A vaginal microbiome dominated by L. iners is, how-
ever, not associated with a proinflammatory profile, and data on whether it increases the risk
of adverse outcomes are conflicting. Vaginal microbiomes with a high relative abundance of
the other vaginal lactobacilli are much less prevalent and less well studied [1,7].
Vaginal dysbiosis is often defined as a prolonged deviation from a low-diversity, lactoba-
cilli-dominated vaginal microbiome. Molecular studies have identified different types of vagi-
nal dysbiosis [1,7]. The most common type is high-diversity anaerobic dysbiosis, almost
always including Gardnerella vaginalis and Atopobium vaginae as well as multiple other anaer-
obes, with or without a low relative abundance of L. iners. Low-diversity anaerobic dysbiosis,
characterized by G. vaginalis or A. vaginae domination, also occurs, albeit less commonly.
Studies employing multiple methods of vaginal microbiome characterization have shown high
correlations between BV by Gram stain Nugent scoring and anaerobic dysbiosis (high and low
diversity combined) [1]. Another type of vaginal dysbiosis that is likely important from a
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clinical point of view is a high relative abundance of pathobionts, also referred to as pathobiont
carriage. Anaerobic dysbiosis and pathobiont carriage have been associated with proinflam-
matory immune profiles and with the above-mentioned adverse outcomes, and anaerobic
dysbiosis has also been associated with cervicomucosal barrier disruption [3]. The roles of Bifi-
dobacteriaceae (other than G. vaginalis) and Corynebacterium in the vaginal microbiome have
not yet been studied, and domination by these bacteria is rare [1,7].
Many epidemiological studies have found that BV, VVC, vaginal pathobiont carriage,
and STIs are interrelated and that many of the associations are bidirectional [8,9]. The
interrelationships could be explained by both behavioral and biological factors. First, many
of these conditions share risk factors related to sexual transmission. While BV, VVC, and
vaginal pathobiont carriage were never considered STIs and can indeed occur in the
absence of sexual activity, it is now clear that sexual transmission of the implicated organ-
isms does play a role, especially in sex with uncircumcised male partners [2,10]. Second,
most dysbiosis types and VVC cause mucosal barrier disruption, which decreases the abil-
ity of mucus and vaginal secretions to trap or inactivate pathogens and creates epithelial
portals of entry, and cervicovaginal inflammation, which increases the concentration of
target cells for HIV at the mucosal sites where HIV exposure takes place [3]. Interestingly,
STIs and anaerobic dysbiosis often overlap, but VVC seems to occur more often in the
presence of lactobacilli-domination than in the presence of anaerobic dysbiosis (Fig 1) [8].
A recent study showed positive associations between vaginal S. agalactiae carriage and vag-
inal Escherichia coli and Candida albicans carriage, but a negative association with anaero-
bic dysbiosis [9]. Many explanations for these associations have been hypothesized, such as
vaginal pH (C. albicans, S. agalactiae, and E. coli are not inhibited by the low vaginal pH
produced by lactobacilli), competition between micro-organisms for nutrients, microbial
defense mechanisms against one another, biofilms that include some micro-organisms but
not others, and attachment of some bacteria to Candida hyphae. Further in-depth charac-
terization of these mechanisms is important because they may lead to new targets for drug
development and an increased understanding of how intervening in one pathway might
influence other pathways.
Implications and challenges
While first-line treatment of BV with oral or vaginal metronidazole or clindamycin is typically
efficacious in the short term (as defined by Nugent or Amsel criteria), recurrence rates are
high [10,11]. Clinical studies have shown that BV recurrence rates can be reduced by longer
duration and/or prophylactic use of first-line antibiotics, by (estrogen-containing) hormonal
contraception, and by circumcision of male sexual partners, but not by adding other antibiot-
ics (azithromycin or moxifloxacin) to first-line antibiotics or by metronidazole/clindamycin
treatment of male sexual partners [11]. Some argue that recurrence is particularly likely when
a mucosal biofilm is present. In vitro and in vivo studies have shown that such a biofilm is
damaged and suppressed by metronidazole but not completely eliminated [12]. The interrela-
tionships between various urogenital conditions also pose challenges. For example, treatment
of anaerobic dysbiosis often leads to VVC [13]. Treatments might be more efficacious in the
longer term when they specifically target dysbiosis-associated anaerobes or pathobionts while
sparing lactobacilli and are combined with biofilm disrupting agents, systemic or topical estro-
gen, and/or Lactobacillus-containing vaginal pro- or synbiotics. Estrogen-containing hor-
monal contraception, and Lactobacillus-containing vaginal pro- or synbiotics if found to be
clinically effective, could also be implemented for routine use on a larger scale to prevent vagi-
nal dysbiosis in women at risk.
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While current knowledge suggests that maintaining lactobacilli-dominant, inflammation-
free vaginal environments could advance the prevention of HIV, STIs, and adverse outcomes,
this would not be an easy task, and many research questions remain. At the moment, the vagi-
nal health of women is seldom routinely checked, even in pregnancy. HIV/STI screening pro-
grams targeting at-risk populations do exist, but otherwise, only women who seek medical
care for urogenital symptoms are likely to be evaluated and treated, often in the absence of any
diagnostic laboratory testing. Further, there is ample evidence that presumptive and syndro-
mic management of urogenital conditions in the absence of any diagnostic testing have low
sensitivity and specificity compared to diagnostic testing followed by treatment [14]. Even if
diagnostic testing were to be introduced in order to optimize vaginal health and minimize
complications, we currently do not know which women to target, when intervention would be
required (i.e., which relative abundances or concentrations of G. vaginalis, A. vaginae, and
pathobionts or which levels of cervicovaginal inflammation should be considered harmful),
and which interventions, or combinations of interventions, would be optimal. However, the
progress made in recent years has made it possible to start contemplating these issues and
work towards solutions.
Fig 1. Visualization of interrelationships among various urogenital conditions involving micro-
organisms. Green colors indicate desirable conditions, and red colors indicate undesirable conditions. In
both cases, the darker the color, the more desirable or undesirable the condition, respectively. The size of the
circles is relative to the size of the respective epidemics, but only very roughly. The STI circle does not include
viral STIs. The circles on the far left and far right appear as if they do not overlap because the image is two
dimensional, but they do overlap somewhat. It is important to note that few studies on the associations
between urogenital conditions and host responses or adverse outcomes (which determine whether a
condition is desirable or undesirable) have been holistic. For example, many studies only employ 16S
ribosomal RNA sequencing of the vaginal microbiota, but this does not cover fungi, protozoa, and viruses and
does not reliably identify Chlamydia trachomatis and Neisseria gonorrhoeae. Abbreviations: GBS, Group B
streptococcus; STI, sexually transmitted infection. * Complications include HIV acquisition, pelvic
inflammatory disease, adverse pregnancy outcomes, and maternal and neonatal infections.
https://doi.org/10.1371/journal.pmed.1002478.g001
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